journal article·2005-11-01

Preparation of novel hollow mesoporous silica spheres and their sustained-release property

Yufang Zhu, Jianlin Shi, Weihua Shen, Hangrong Chen, Xiaoping Dong, Meilin Ruan

Nanotechnology· Volume 16· Issue 11
Publisher page

Abstract

Novel hollow mesoporous silica spheres (HMSs) with uniform size and morphology have been successfully synthesized in a facile route using poly(vinylpyrrolidone) (PVP) and cetyltrimethylammonium bromide (CTAB) as co-templates at room temperature. XRD, N2 adsorption–desorption analysis, FE-SEM, and TEM are used for the characterization of the structure. The hexagonally ordered pore channels are formed on the shell. Ibuprofen (IBU) as a model drug is used to examine the storage capacity and the release behaviour of drug molecules. The storage capacity of hollow mesoporous silica spheres can reach 1133 ± 52.4 mg g−1 for ibuprofen, which is three times higher than that of conventional mesoporous materials previously reported (337 mg g−1), and the storage capacity is adjustable in a wide range. Furthermore, this system also shows a sustained-release behaviour. The release rates from the IBU-HMSs system (IBU stored in HMSs) increase with the decrease of pH values and the release process follows a Fick's law.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Mesoporous Materials and Catalysis · Analytical Chemistry and Chromatography · Metal-Organic Frameworks: Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Colombo P · Eur. J. Drug Metab. Pharmacokinet. · 1996 · 2 · 8710.1007/BF03190256 ↗
2. Rathbone M J · Modified Release Drug Delivery Technology · 2003
3. 10.1002/anie.20039010810.1002/anie.200390108 ↗
4. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
5. 10.1016/S1461-5347(00)00268-610.1016/S1461-5347(00)00268-6 ↗
6. 10.1016/S0169-409X(01)00154-510.1016/S0169-409X(01)00154-5 ↗
7. Couvreur P · Eur. J. Pharm. Biopharm. · 1995 · 41 · 2
8. 10.1038/359710a010.1038/359710a0 ↗
9. 10.1006/jcis.1997.492610.1006/jcis.1997.4926 ↗
10. 10.1016/j.jnoncrysol.2004.06.00410.1016/j.jnoncrysol.2004.06.004 ↗
11. 10.1016/S0142-9612(99)00148-910.1016/S0142-9612(99)00148-9 ↗
12. 10.1002/(SICI)1097-4636(199902)44:2<162::AID-JBM6>3.0.CO;2-P10.1002/(SICI)1097-4636(199902)44:2<162::AID-JBM6>3.0.CO;2-P ↗
13. 10.1002/adma.20040077110.1002/adma.200400771 ↗
14. 10.1021/cm001155910.1021/cm0011559 ↗
15. 10.1021/cm021217q10.1021/cm021217q ↗
16. 10.1016/j.micromeso.2003.12.01210.1016/j.micromeso.2003.12.012 ↗
17. 10.1002/chem.20030476410.1002/chem.200304764 ↗
18. Tourné-Péteilh C · Chem. Phys. Chem. · 2003 · 3 · 28110.1002/cphc.200390045 ↗
19. 10.1021/ja028650l10.1021/ja028650l ↗
20. 10.1021/cm981061n10.1021/cm981061n ↗
21. 10.1023/A:102076431996310.1023/A:1020764319963 ↗
22. 10.1039/b307046h10.1039/b307046h ↗
23. 10.1038/nature0136210.1038/nature01362 ↗
24. 10.1021/cm034329610.1021/cm0343296 ↗
25. 10.1016/j.jconrel.2004.03.00510.1016/j.jconrel.2004.03.005 ↗
26. 10.1557/JMR.2005.003510.1557/JMR.2005.0035 ↗
27. 10.1016/j.materresbull.2005.02.01110.1016/j.materresbull.2005.02.011 ↗
28. 10.1021/ja015875810.1021/ja0158758 ↗
29. Chen J · Inorg. Chem. Commun. · 2004 · 44710.1016/j.inoche.2004.01.003 ↗
30. 10.1016/S1359-0294(00)00089-310.1016/S1359-0294(00)00089-3 ↗
31. Yu C · Chem. Lett. · 2002 · 6210.1246/cl.2002.62 ↗
32. Lin H-P · Chem. Commun. · 2001 · 197010.1039/b104600b ↗
33. 10.1021/nl034134x10.1021/nl034134x ↗
34. Schacht S · Science · 1996 · 273 · 76810.1126/science.273.5276.768 ↗
35. Fowler C E · Chem. Commun. · 2001 · 202810.1039/b104879c ↗
36. 10.1016/j.jconrel.2004.06.00510.1016/j.jconrel.2004.06.005 ↗
37. Peppas N A · Pharm. Acta Helv. · 1985 · 60 · 110
38. 10.1023/A:102298393254810.1023/A:1022983932548 ↗
39. 10.1038/359710a010.1038/359710a0 ↗
40. 10.1021/la000176e10.1021/la000176e ↗
41. 10.1021/la000834v10.1021/la000834v ↗
42. 10.1021/la010201w10.1021/la010201w ↗